Biologic
On-demand sebetralstat effective for hereditary angioedema attacks in larynx
SAN DIEGO — Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with oral sebetralstat, preventing potentially fatal outcomes, according to an abstract presented here.
Chronic rhinosinusitis with nasal polyps improves with tezepelumab
SAN DIEGO — Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to an abstract presented here.
Risk factors impact denials, wait times, discontinuations in biologic treatment for asthma
SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.
Eosinophilic granulomatosis with polyangiitis remission achieved with benralizumab
SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.
Twice-yearly depemokimab for asthma tolerated well as exacerbation rates fall
SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract presented here.
Median hereditary angioedema attack rates fall to zero for children with berotralstat
SAN DIEGO — Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a median of zero after the first month and at 12 months, according to a poster presented here.
‘Tsunami of effort’ brings biologics to the forefront in giant cell arteritis, PMR
Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host of related toxicities and adverse effects — has long been a goal for rheumatologists.
Public insurance leads to faster bDMARD initiation in juvenile idiopathic arthritis
WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public insurance vs. private, particularly if they have oligoarticular JIA, according to a speaker.
Consider blood eosinophil counts when selecting biologic in COPD
PHILADELPHIA — The current biologics for patients with COPD include anti-IL-5 therapies, dupilumab, tezepelumab and anti-IL-33 therapies, according to a presentation at the 2024 GOLD COPD International Conference.
VIDEO: Verséa focused on diagnostic technologies, biologic solutions for eye care
INDIANAPOLIS — Verséa Ophthalmics recently has introduced several new technologies for eye care, including the Biovance 3L Ocular amniotic membrane allograft and the T-POC quantitative testing platform for ocular surface disease.